Mentari Therapeutics secures second $200M private placement to fund migraine program and advance reverse merger

Mentari Therapeutics, a spin‑out focused on migraine treatments, announced it has arranged a second private‑placement financing of $200 million.

The new capital will be used to advance its migraine drug pipeline and to help complete a pending reverse merger with InMed Pharmaceuticals, which would provide a public market vehicle for the company.

In a separate note, Royalty Pharma disclosed a recent transaction involving an ATTR‑CM (transthyretin amyloid cardiomyopathy) asset, underscoring continued activity in rare‑disease licensing deals.